Alpine: Is This A Young Oak Tree?

Summary

• Alpine Immune Sciences is a stellar growth bio-stock that is reaching a point of growth inflection.
• Back in June last year, Alpine secured a highly favorable partnership with AbbVie.
• Alpine's lead candidates ALPN-101 and ALPN-202 are rapidly advancing in development.

Know what you own, and know why you own it. - Peter Lynch

According to Warren Buffett, being patient and waiting for the right opportunity is the key to successful long-term investing. Resonating with the principle is my investing story with Alpine Immune Sciences (ALPN). As you know, Mr. Buffett is not known as an exclusive biotech investor. However, certain investing principles transcend across sectors. That being said, don't shoot the messenger. Listen to my message.

Starting in late 2017, I recommended Alpine for over two consecutive years. In that time span, the stock disappointed investors. Still, I did not give up on Alpine because of its strong underlying science. Earlier this year, the AbbVie (ABBV) partnership catapulted Alpine shares over 80%. Following the current raging bull market, Alpine is resurging to a new high. Despite tremendous profits, I believe there are substantial upsides to this investment story. In this research, I'll feature a fundamental update on Alpine and provide my forward expectations of this Philip Fisher's growth equity. Of note, a Fisher's growth biotech is one that met my M4 criteria that I adapted from Fisher's criteria.

Figure 1: Alpine chart (Source: StockCharts)

About The Company

As usual, I'll present a brief corporate overview for new investors. If you are familiar with the firm, I suggest that you skip to the subsequent section. Headquartered in Seattle Washington, Alpine is focused on the innovation and commercialization of stellar medicine that modulates the body's natural defense (i.e., immune) system for the treatment of autoimmune diseases and cancers.

Riding a powerful technology known as Variant Immunoglobulin Domain (vIgD), Alpine is brewing an intriguing pipeline. Asides from the lead medicine ALPN-101, I also like ALPN-202 and ALPN-303. Of note, whenever you invest in early-stage biotech like Alpine, check to see if it has a partner. On this front, it's a great sign

Analyst’s Disclosure:I am/we are long ALPN. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

As a medical doctor/market expert, I’m not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I am also NOT responsible for the actions of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investment in stocks and options can result in a loss of capital. The information presented should NOT be construed as a recommendation to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your actions. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized.